KITE News
Archived Headlines
- Double dose of immunotherapy: Bellicum Pharmaceuticals sets terms for $100 million IPO 12/09/14
- Year's biggest biotech: Juno Therapeutics sets terms for $153 million IPO 12/09/14
- Cancer biotech Bellicum Pharmaceuticals files for a $115 million IPO 11/18/14
- The next big cancer biotech: Juno Therapeutics files for a $150 million IPO 11/17/14
- Immunotherapy biotech Tobira Therapeutics sets terms for $60 million IPO; researching HIV and NASH 07/21/14
See more
Renaissance IPO Index - Notice of September 2015 Quarterly Changes
The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s...read more
Pancreatic cancer biotech Aduro files for a $86 million IPO
Aduro Biotech, which is developing an immunotherapy for pancreatic cancer, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering. 2014 immuno-oncology biotech IPOs have traded well, including Kite Pharma (KITE; +287%),...read more
Gene-edit the cancer out: Cellectis files for a $115 million US IPO
Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T-cells, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The company currently trades on the Alternext market of the Euronext Paris under...read more
Gene therapy biotech Spark Therapeutics sets terms for $88 million IPO
Spark Therapeutics, which is developing gene therapy treatments for retinal dystrophies and hematologic disorders, announced terms for its IPO on Tuesday. The Philadelphia, PA-based company plans to raise $88 million by offering 5.5 million shares at a price...read more